RIPK1, or receptor-interacting protein kinase 1, sits at a fork in the road inside nearly every cell in your body. Depending on how it is modified and which partners it binds, it can flip a switch that keeps a cell alive and quiet, or it can trigger the cell’s violent death and spark inflammation. That dual personality makes RIPK1 one of the most intensely studied signaling molecules in modern biology, with implications stretching from Alzheimer’s disease and ALS to liver failure, inflammatory bowel disease, and cancer. Several drug candidates designed to block its death-promoting activity have already entered clinical trials in humans.
A Molecular Switch Between Life and Death
What makes RIPK1 unusual is that it can do two opposing things. As a physical scaffold, it holds together a protein complex that activates survival signals, keeping the cell alive and suppressing inflammation. But when its enzymatic (kinase) activity is switched on, RIPK1 instead assembles death-inducing complexes that kill the cell and release inflammatory molecules into surrounding tissue. Mice that completely lack RIPK1 die shortly after birth because runaway cell death goes unchecked, underscoring how critical the scaffold function is for normal tissue survival.1PubMed Central. The scaffold-dependent function of RIPK1 in dendritic cells promotes injury-induced colitis
This duality has been studied most clearly in the liver. In experimental models of fatty liver disease, blocking RIPK1’s kinase activity with drugs reduced hepatocyte death and liver inflammation. Yet deleting RIPK1 entirely from hepatocytes made things worse, because the cells lost the scaffold-mediated brake on death signaling and underwent both necroptosis and apoptosis spontaneously.2Europe PMC. The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis The takeaway for drug development is that you want to silence RIPK1’s kinase without destroying the protein itself.
How the Cell Keeps RIPK1 in Check
Left unregulated, RIPK1’s kinase activity would be catastrophic. The cell uses two main chemical tags to keep RIPK1 restrained: ubiquitin chains and phosphate groups. When a cell receives an inflammatory signal such as TNF-alpha, RIPK1 is rapidly recruited into a receptor-associated complex and tagged with ubiquitin chains. That ubiquitination promotes survival signaling and suppresses death. Mutating a key ubiquitin-acceptor site on RIPK1 (lysine 377 in humans) made cells far more sensitive to TNF-induced killing, even though they could still activate some survival signaling. The researchers described this as an anti-apoptotic effect that appeared to operate independently of the classical survival pathway.3Current Biology. Ubiquitination of RIP1 Regulates an NF-κB-Independent Cell-Death Switch in TNF Signaling
A similar checkpoint operates at a different ubiquitin site. In mouse cells, mutating lysine 612 (the equivalent of human lysine 627) significantly reduced RIPK1’s recruitment into the receptor complex and weakened the downstream activation of survival signals like NF-κB and MAP kinases.4Nature Communications. Ubiquitination of RIPK1 regulates its activation mediated by TNFR1 and TLRs signaling in distinct manners Importantly, this mutation also blocked RIPK1’s own kinase activation, so the net effect was actually less cell death rather than more, because the death-promoting function was suppressed even more than the survival function was weakened.
On the other side of the ledger, removing ubiquitin from RIPK1 can push the system toward death. The enzyme CYLD strips ubiquitin chains from RIPK1 within the necrosome, the death-inducing complex. When CYLD is blocked, RIPK1 stays heavily ubiquitinated, and its kinase activity along with the kinase activity of its partner RIPK3 is impaired.5PubMed Central. CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis So the balance between ubiquitin-adding enzymes and ubiquitin-removing enzymes plays a tug-of-war that determines whether RIPK1 stays inactive or becomes a death-promoting kinase.
Phosphorylation adds another layer. The kinase TAK1 phosphorylates RIPK1 at a specific site (serine 321 in mice), and this phosphorylation prevents RIPK1 from becoming activated. When that phosphorylation is blocked, RIPK1 flips into its active form and recruits the adapter protein FADD to trigger apoptosis.6PubMed Central. Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis Yet another checkpoint involves caspase-8, an enzyme that physically cuts RIPK1 apart. Humans who carry mutations that prevent caspase cleavage of RIPK1 develop an early-onset autoinflammatory syndrome characterized by recurrent fevers and severe lymph node swelling.7PubMed Central. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease That finding in living patients confirmed what years of animal studies had suggested: if RIPK1 cannot be kept in check, chronic inflammation follows.
Building the Necrosome
When survival signals fail and RIPK1’s kinase becomes active, it binds to RIPK3 through a shared structural motif. Together they form a complex called the necrosome.8PubMed. Surviving death: emerging concepts of RIPK3 and MLKL ubiquitination in the regulation of necroptosis RIPK3, once activated, phosphorylates a protein called MLKL, which then migrates to the cell membrane, punches holes in it, and the cell ruptures.9PubMed Central. Regulation of RIPK3- and RHIM-dependent Necroptosis by the Proteasome This mode of death, called necroptosis, is inherently inflammatory because the broken-open cell dumps its contents into surrounding tissue, alerting the immune system.
Recent structural work has revealed something striking about how RIPK1 and RIPK3 interact. Using cryo-electron microscopy, researchers found that the RHIM domains of RIPK1 and RIPK3 assemble into amyloid-like fibrils, structures more commonly associated with neurodegenerative diseases. Both RIPK1-only fibrils and mixed RIPK1/RIPK3 fibrils share a similar S-shaped configuration with a helical pitch of roughly 23 nanometers.10PubMed Central. Intercellular propagation of RIPK1/RIPK3 amyloid fibrils The shared architecture may explain how necroptosis signals can propagate from cell to cell, potentially amplifying tissue damage in disease.
RIPK1 in the Brain
Some of the most compelling disease-related findings involve the central nervous system. In Alzheimer’s disease, RIPK1 is highly expressed in the brain’s immune cells, microglia. In a mouse model of Alzheimer’s, inhibiting RIPK1 reduced amyloid plaque burden, lowered inflammatory cytokine levels, and improved memory deficits. The mechanism was not simply about preventing cell death. RIPK1 appeared to drive microglia into a dysfunctional “disease-associated” state in which they produced more inflammation and lost their ability to clear amyloid debris through phagocytosis. RIPK1 did this partly by upregulating an enzyme called Cystatin F that impairs the cell’s waste-disposal machinery.11PubMed Central. RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease This non-cell-death role of RIPK1, essentially reprogramming immune cells rather than killing neurons directly, expanded the field’s understanding of what RIPK1 does in disease.
In amyotrophic lateral sclerosis, the connection is more directly linked to necroptosis. Loss of the protein optineurin, which is mutated in some ALS patients, led to progressive myelin loss and axonal degeneration in mice through RIPK1-RIPK3-MLKL-dependent necroptosis. RIPK1- and RIPK3-mediated axonal damage was also observed in SOD1 transgenic mice, a widely used ALS model, and in pathological samples from human ALS patients.12PubMed Central. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS The presence of necroptotic signatures in actual human tissue samples, not just animal models, strengthens the case that blocking RIPK1 could slow motor neuron degeneration.
Gut Inflammation and the Intestinal Barrier
The intestinal lining is one of the body’s most active sites of cell turnover, and necroptosis in intestinal epithelial cells has been linked to inflammatory bowel disease. Barrier breakdown allows gut bacteria and their products to penetrate the tissue, fueling a cycle of cell death and immune activation.13PubMed Central. The Function of Necroptosis and Its Treatment Target in IBD In an experimental colitis model, treating with a RIPK1 inhibitor reduced disruption of tight junctions (the seals between intestinal cells), suppressed oxidative stress, and decreased the release of immune-recruiting signals from damaged cells. These protective effects came partly from blocking necroptosis and partly from dampening the NF-κB inflammatory pathway, suggesting RIPK1 inhibitors may hit the disease from two angles at once.14PubMed. RIPK1 inhibitor ameliorates colitis by directly maintaining intestinal barrier homeostasis and regulating following IECs-immuno crosstalk
Ischemia-Reperfusion Injury
When blood supply to an organ is cut off and then restored, a burst of necroptotic cell death can occur in the tissue. This happens during heart attacks, strokes, and organ transplants. RIPK1 plays a central role in this process, and early studies showed that necrostatin-1, the original tool-compound inhibitor of RIPK1, protected the kidney, heart, and brain from ischemia-reperfusion damage in animal models.15PubMed. Necroptosis in immunity and ischemia-reperfusion injury This line of evidence was actually one of the first strong signals that targeting RIPK1 might have clinical utility beyond the laboratory, since ischemia-reperfusion injury is a major cause of organ damage in transplant medicine and emergency cardiology.
Cancer and the Tumor Microenvironment
RIPK1’s role in cancer is more complex and sometimes counterintuitive. The tumor microenvironment is shaped by cell death, inflammation, and immune cell behavior, all of which RIPK1 influences. In one lung cancer study, mice with a kinase-dead version of RIPK1 developed about 38% fewer tumor nodules than normal mice, while knocking out RIPK3’s kinase activity had no effect on tumor number.16PubMed Central. Innovative Approaches Targeting RIPK1 to modulate cell death and tumour microenvironment in cancer therapy This suggests that RIPK1’s kinase activity specifically promotes a tumor-friendly environment, at least in some cancer types, and raises the possibility that RIPK1 inhibitors developed for neurodegeneration might find additional use in oncology.
The picture is not entirely straightforward, though. Because necroptosis is an immunogenic form of cell death, triggering it within tumors can in theory alert the immune system and promote anti-tumor responses. Whether to inhibit or activate RIPK1-dependent death in cancer likely depends on the tumor type and the immune context, and this remains an area of active investigation.
PANoptosis and Emerging Concepts
The traditional view splits cell death into neat categories: apoptosis (quiet, programmed), necroptosis (inflammatory, RIPK-driven), and pyroptosis (inflammatory, driven by inflammasomes). But the emerging concept of PANoptosis blurs these lines. PANoptosis describes a situation where apoptosis, necroptosis, and pyroptosis are activated simultaneously through crosstalk among their molecular components. RIPK1 sits at the intersection of at least two of these pathways. This coordinated death process has been linked to the severe cytokine storm seen in SARS-CoV-2 infection, where the immune system’s overreaction causes widespread tissue damage.17PubMed. PANoptosis as a Therapeutic Target for COVID-19 If PANoptosis turns out to be a common feature of severe infections and hyperinflammatory syndromes, RIPK1 inhibitors could become relevant to a broader set of conditions than initially imagined.
RIPK1 Inhibitors Reaching Human Trials
The earliest RIPK1 inhibitors were tool compounds called necrostatins, and they work in an unusual way. Rather than competing for the ATP-binding pocket used by most kinase inhibitors, necrostatins bind to a separate allosteric pocket between two lobes of RIPK1’s kinase domain and lock it in an inactive conformation. This makes them “type III” kinase inhibitors, a class known for high selectivity because the pocket they target is unique to RIPK1 rather than shared across the hundreds of kinases in the human genome.18Cell Discovery. Discovery of a cooperative mode of inhibiting RIPK1 kinase Structural studies confirmed that the inhibitor displaces a critical helix in the kinase domain by roughly 40 degrees, physically preventing the enzyme from adopting its active shape.19Journal of Medicinal Chemistry. From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors – Section: 4.1.1. Necrostatins
Several next-generation compounds have progressed into human trials. SAR443060 (also known as DNL747) was one of the first to be tested in patients with Alzheimer’s and ALS. It entered the cerebrospinal fluid after oral dosing and showed strong peripheral target engagement, measured by a drop in the phosphorylated (active) form of RIPK1. It was generally well tolerated in healthy volunteers and patients, but its development was ultimately stopped because of findings in long-term animal toxicology studies, even though those signals were not observed in the short-duration human trials.20PubMed Central. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients
Its successor, SAR443820 (DNL788), was designed to address those issues and showed promising results in healthy volunteers. The drug was well tolerated with no treatment discontinuations due to adverse events. After repeated dosing, it achieved close to 90% inhibition of activated RIPK1 at trough levels, and its brain penetration was high, with cerebrospinal fluid concentrations closely matching unbound plasma levels. These results supported its advancement into phase II trials for ALS and multiple sclerosis.21PubMed Central. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants
Another compound, SIR9900, demonstrated a similar profile in a trial that included both younger and older adult volunteers. It achieved roughly 90% peripheral target engagement within three hours of dosing, sustained RIPK1 inhibition over a 10-day treatment period, and showed a cerebrospinal fluid-to-unbound-plasma ratio of 1.15, indicating good brain entry. The drug’s exposure was similar between younger and older participants, which matters because neurodegenerative diseases primarily affect older adults.22PubMed Central. Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor (SIR9900) in Healthy Adults and Elderly Participants
Why Selectivity Matters for Safety
The fact that RIPK1 is needed for cell survival in its scaffold role creates an inherent risk for any therapy that targets the protein. Completely removing RIPK1 function, as genetic knockout studies in mice demonstrate, is lethal. The therapeutic strategy therefore depends on selectively silencing the kinase activity while leaving the scaffold intact. The allosteric binding mode of necrostatin-derived inhibitors is well suited to this because it freezes the kinase in an inactive shape without disrupting the protein’s physical interactions with survival-signaling partners. Early clinical data showing that compounds like SAR443820 and SIR9900 are well tolerated with robust target engagement is encouraging, but longer-term safety in patients with chronic disease remains to be established. The discontinuation of SAR443060 because of long-term animal toxicology findings is a reminder that even selective kinase inhibition can produce unexpected effects when sustained over months or years.
What RIPK1 Research Reveals About Inflammation More Broadly
One reason RIPK1 has attracted so much attention is that it challenges a once-common assumption that cell death and inflammation are separate processes best studied independently. RIPK1 sits at the nexus of the two. When it drives necroptosis, dying cells release inflammatory signals. When it reprograms microglia in the brain, it changes immune cell behavior without killing neurons. When its cleavage by caspase-8 fails in human patients, the result is periodic fevers and inflammatory episodes rather than a cell-death syndrome in the traditional sense. The protein keeps revealing new ways that death signaling and immune activation are wired together. For researchers working on conditions ranging from transplant rejection to neurodegeneration to severe viral infections, RIPK1 has become a kind of rosetta stone for understanding how tissue damage and immune responses feed into each other at the molecular level.